Henry Schein, Inc. (NASDAQ:HSIC) Short Interest Down 5.9% in June

Henry Schein, Inc. (NASDAQ:HSIC) was the recipient of a significant drop in short interest in June. As of June 30th, there was short interest totalling 18,449,900 shares, a drop of 5.9% from the May 30th total of 19,612,500 shares. Approximately 12.4% of the company’s shares are short sold. Based on an average daily trading volume, of 1,450,000 shares, the days-to-cover ratio is presently 12.7 days.

Shares of HSIC traded up $0.33 on Monday, reaching $70.91. The stock had a trading volume of 2,354 shares, compared to its average volume of 1,242,040. The stock has a market cap of $10.52 billion, a price-to-earnings ratio of 17.09, a PEG ratio of 2.47 and a beta of 0.84. The company has a debt-to-equity ratio of 0.34, a current ratio of 1.65 and a quick ratio of 0.93. The company’s 50-day moving average is $68.96. Henry Schein has a twelve month low of $56.58 and a twelve month high of $91.35.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings data on Tuesday, May 7th. The company reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.76 by $0.04. Henry Schein had a return on equity of 18.35% and a net margin of 4.10%. The business had revenue of $2.36 billion for the quarter, compared to analysts’ expectations of $2.36 billion. During the same quarter last year, the firm earned $0.95 earnings per share. The business’s revenue was up 3.8% on a year-over-year basis. As a group, equities analysts anticipate that Henry Schein will post 3.45 EPS for the current year.

In other Henry Schein news, EVP Gerald A. Benjamin sold 19,630 shares of Henry Schein stock in a transaction on Wednesday, June 19th. The stock was sold at an average price of $72.02, for a total value of $1,413,752.60. Following the sale, the executive vice president now owns 113,832 shares in the company, valued at $8,198,180.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Steven Paladino sold 20,712 shares of Henry Schein stock in a transaction on Wednesday, June 19th. The shares were sold at an average price of $72.17, for a total value of $1,494,785.04. Following the completion of the sale, the chief financial officer now owns 166,233 shares in the company, valued at approximately $11,997,035.61. The disclosure for this sale can be found here. In the last quarter, insiders have sold 49,668 shares of company stock worth $3,572,423. 1.06% of the stock is currently owned by company insiders.

Several institutional investors and hedge funds have recently modified their holdings of HSIC. BlackRock Inc. raised its position in Henry Schein by 2.4% in the first quarter. BlackRock Inc. now owns 11,389,688 shares of the company’s stock valued at $684,635,000 after purchasing an additional 271,586 shares during the period. JPMorgan Chase & Co. grew its stake in shares of Henry Schein by 22.1% during the first quarter. JPMorgan Chase & Co. now owns 2,426,917 shares of the company’s stock valued at $145,882,000 after acquiring an additional 439,922 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Henry Schein by 8.3% during the fourth quarter. Geode Capital Management LLC now owns 2,105,314 shares of the company’s stock valued at $165,038,000 after acquiring an additional 161,542 shares in the last quarter. Northern Trust Corp grew its stake in shares of Henry Schein by 1.2% during the first quarter. Northern Trust Corp now owns 1,938,599 shares of the company’s stock valued at $116,529,000 after acquiring an additional 23,694 shares in the last quarter. Finally, Boston Partners acquired a new stake in shares of Henry Schein during the first quarter valued at about $99,903,000.

Several research analysts have recently issued reports on HSIC shares. BidaskClub raised Zebra Technologies from a “hold” rating to a “buy” rating in a research report on Saturday, July 6th. Wolfe Research assumed coverage on Waters in a report on Thursday, May 30th. They issued an “underperform” rating for the company. Cleveland Research reissued a “hold” rating on shares of Henry Schein in a report on Thursday, May 2nd. Guggenheim assumed coverage on Patterson Companies in a report on Wednesday, April 17th. They issued a “neutral” rating and a $23.00 target price for the company. Finally, Robert W. Baird reissued a “neutral” rating on shares of Henry Schein in a report on Monday, March 25th. Seven equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and four have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $74.13.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.

Featured Story: Understanding Compound Annual Growth Rate (CAGR)

Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.